A Prospective, Observational, Multicenter Study Comparing Tenecteplase Facilitated PCI Versus Primary PCI in Indian Patients with STEMI

Sampa Malini Victor1, Vijayadasan Subban1, Thomas Alexander2, Bahuleyan C. Gopalan3, Srinivas4, Selvamani Sethuraman5, Aji S. Mullarasi6, 1Madras Medical Mission, Chennai, India, 2Kovai Medical Centre and Hospital, Coimbatore, India, 3Ananthapuri Hospitals and Research Institute, Trivandrum, India, 4Vikram Group of Hospitals, Mysore, India, 5Meenakshi Mission Hospital and Research centre, Madurai, India

Background: Primary PCI in STEMI is the preferred treatment, but not a feasible option for many and pharmacoinvasive therapy might be a practical solution in the Indian context. The objective of this study is to assess the efficacy of pharmacoinvasive strategy in STEMI patients versus primary PCI.

Methods: This is an observational, multicenter study that prospectively enrolled 200 patients with STEMI. Patients who were fibrinolysed (n = 45) formed arm ‘A’ and underwent CAG within 3-24 hours with coronary intervention as appropriate. Arm ‘B’ consisted of patients who opted for primary PCI (n = 155). Primary endpoint was composite of death, cardiogenic shock, reinfarction, repeat revascularization or congestive heart failure up to 1 year.

Results: The IRA patency at angiogram was 82.2% in arm A and 22.6% in arm B (p < 0.001). PCI was performed in 73.3% vs 100% (p < 0.001); thrombus was present in 69.7% vs 63.2% (p < 0.001) in arm A & B respectively. Significantly more number of patients in arm A had TIMI 3 flow in the culprit vessel at angiogram than arm B, 27.9% vs 4.5% (p < 0.001). Failed fibrinolysis occurred in 12.1%. Total ischemic time was 245 minutes (185-395) for arm A and 260 minutes (385-390) for arm B. There was no difference in bleeding risk. Primary end point occurred in 13.3% in arm A and 9% in arm B. p = 0.40, (OR 0.64; 95% CI 0.24-1.79).

Conclusion: Pharmacoinvasive strategy resulted in comparable outcomes as primary PCI at 1 year. Larger RCTs are required to confirm these findings.

TCTAP A-010

Kaplan-Meier curve for in-hospital 30 days mortality according to the Killip classification

Bifurcation lesion is a major determinant of lower procedural success rates and adverse outcomes. Pharmacoinvasive strategy resulted in comparable outcomes as primary PCI.

TCTAP A-012

The Protective Effect of Aspiration Thrombectomy on Side Branch Compromise and Twelve Months Clinical Outcomes in AMI with Bifurcation Lesion Undergoing Primary PCI

Je Young Park, Jogyoong Park, Sangker Rh, Changsup Song

Eaj General Hospital, Seoul, Korea (Republic of)

Background: Bifurcation lesions (BF) remains a challenging lesion subset, often associated with lower success rates. Side branch (SB) compromise in bifurcation lesions is a major determinant of lower procedural success rates and adverse outcomes. Ascension thrombectomy (AT) prevent distal embolization in acute myocardial infarction (AMI). The aim of this study is to evaluate the protective effect of AT on SB compromise in BF lesions and twelve months clinical outcomes in AMI patients undergoing primary percutaneous coronary intervention (PCI).

Methods: A total of 201 AMI patients with bifurcation lesion undergoing PCI were analyzed between 2007 and 2011. The patients were divided into two groups according to use of AT (AT group: n = 74, non AT group: n = 127).

We compared Thrombolysis In Myocardial Infarction (TIMI) of main and side branch at 12 months clinical outcomes including mortality, reinfarction, target lesion revascularization (TLR), and major adverse cardiac event (MACE) including mortality, reinfarction, and TLR.

Results: Baseline clinical characteristics were similar between two groups. Angiographic characteristics showed that LAD lesion was higher in non AT group (39.2% vs 54.8%, p = 0.04) and RCA lesion was higher in AT group (45.9% vs 31.7%, p = 0.050). Visible thrombus (94.6% vs 65.3%, p < 0.001) and the use of GP IIb/IIIa inhibitor (43.2% vs 27.6%, p = 0.030) was higher in AT group. PreTIMI was similar between two groups. However, post TIMI 3 flow was higher in AT group (94.4% vs 80.2%, p < 0.033). However, there were no difference of 12 months clinical outcomes including mortality (5.4% vs 9.1%, p = 0.708), reinfarction (5.4% vs 12.1%, p = 0.324), TLR (0.0% vs 3.0%, p = 0.535), and MACE (13.5% vs 28.8%, p = 0.003). Kaplan-Meier curve showed that the cumulative incidence of MACE was similar between two groups (Log rank = 0.196).

Conclusion: In the present study, AT is related to post TIMI 3 flow in AMI patients with BF lesion undergoing primary PCI. However, cumulative incidence of MACE was similar between two groups.

TCTAP A-013

Prognostic Importance of Killip Classification in Modern Pharmacoinvasive Treatment Era for the Patients with Acute Myocardial Infarction

Tairo Kurita1, Naoto Kumagai2, Koou Hoshino3, Tetsuya Seko4, Takafumi Kojii, Katsutoshi Makino2, Jun Masuda2, Takashi Tanigawa2, Mashio Nakamura2, 1Nagai Hospital, Tsu, Japan, 2NAG Hospital, Tsu, Japan

Background: During the last decades, as the treatment for acute myocardial infarction (AMI) has been improved, in-hospital mortality of AMI has been decreased. Accordingly, the purpose of this study was to ensure and reassess the importance of Killip classification in modern pharmacoinvasive treatment era compared with other common prognostic variables.

Methods: From January 2013 to July 2013, we analyzed information from 250 patients with AMI in Mie CCU registry data. They were categorized to Killip 1, 2/3 (heart failure) and 4 of Killip classification.

Results: Overall in-hospital mortality was 11.4%. Higher Killip classification was associated with higher in-hospital mortality (21.2% in Killip 1, 6.8% in 2/3, 45.9% in 4; P < 0.0001. See figure). According to the multivariate analysis, Killip classification, serum-creatinine and postprocedural TIMI flow were independent predictor for in-hospital mortality. In addition, Killip classification is the strongest independent predictor with hazard ratio of 7.3 compared to other factors.

Conclusion: Killip classification is still powerful independent predictor for in-hospital mortality. In comparison with the studies for the last several decades, in-hospital mortality in patients with Killip 1 and 2/3 at modern treatment era was lower.
TCTAP A-014

Correlation Between the Age of Thrombus and Short Term Clinical Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention

Elizabeth Joseph Fischer, Sanitha Thomas, Prathap Mohan, Latha Abraham, Anna Mathlai, Elizabeth Joseph, Vicky Georgekutty, Merin Baby, Anoop Mathew, Louie Fischer, Eappen Punnose

MOSC Medical College Hospital, Kochi, India

Background: There is some data that plaque instability precedes the onset of symptoms in acute myocardial infarction. But it is not known whether the age of thrombus has any relation to short term clinical outcomes in patients treated with thrombus aspiration during primary percutaneous coronary intervention (PPCI).

Methods: Consecutive patients of ST elevation myocardial infarction (STEMI) undergoing PPCI with thrombus aspiration were included in the present study. After passing the wire in the culprit artery, thrombus aspiration was done with a suction catheter and the material was sent to histopathology lab in 10% formalin. It was processed and the microscopic sections were categorised into old and fresh thrombus, according to the existing guidelines. 30 day major adverse cardiac events (MACE) defined as the composite of death, recurrent myocardial infarction (MI) and revascularisation was calculated with age of the thrombus, after adjusting for confounding factors.

Results: Baseline characteristics like age, sex, presence of risk factors and background statin therapy were similar between the two groups. Of the total number of 79 patients who presented within 6 hours of symptom onset, the aspirated material was insufficient in 7 patients. Out of the remaining 72 thrombi aspirated 40 (55.6%) showed lytic changes and were classified as old. The rest 32 (44.4%) thrombi belonged to the fresh category with intact leukocytes and fibrin. There was no MACE at 30 days in either of the categories.

Conclusion: In patients of STEMI undergoing PPCI short term clinical outcomes are excellent irrespective of the age of the thrombus. However this study needs further evaluation in a larger population with long term follow up.

TCTAP A-015

Required Multiple Aspiration Is the Sign of High Risk of Distal Embolization in Acute Myocardial Infarction

Koshi Matsuo, Yasunori Ueda, Ryuta Sugihara

Osaka Police Hospital, Osaka, Japan

Background: Slow-flow/no re-flow phenomenon is mainly induced by distal embolization of thrombus and necrotic core during PCI of AMI and is associated with unfavorable long-term clinical outcomes. Firstly, we perform aspiration thrombectomy for AMI patients, but we will sometimes experience slow flow or no re-flow phenomenon during PCI, by the presence of distal embolization. However, the high risk patients of distal embolization are not well understood. Various imaging modalities have failed to detect high risk patients of distal embolization for whom distal protection might be beneficial. We examined if the patients who require multiple aspiration to achieve TIMI III flow are high risk of patients of distal embolization.

Methods: Consecutive patients with AMI (n=181) who received PCI with filter-type distal protection device (Filtertrap) were prospectively included. We classified them into two groups by numbers of aspirations required to achieve TIMI III coronary flow: single aspiration (Group A, n=92) and multiple aspiration (Group B, n=43). We compared between the groups the frequency of filter slow flow or no re-flow phenomenon and of distal embolization captured by filter device. Distal embolization was evaluated by the pathological examination of collected material in the filter device.

Results: Although the distal embolization of thrombus was not deferent between the groups (100% vs. 96%, P=0.16), that of plaque debris was more frequent in Group B than in Group A (95% vs. 18%, P<0.0001). Filter slow flow/no-reflow phenomenon also occurred more frequently in Group B than in Group A (95% vs. 18%, P<0.0001).

Conclusion: Requirement of multiple aspirations to achieve TIMI III coronary flow was associated with high frequency of distal embolization and of filter slow flow/no-reflow.

TCTAP A-016

The Impact of First- Versus Second-generation Drug-eluting Stent on 1-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Coronary Intervention

Pyung Chan Oh, Woong Chol Kang, Jong Goo Seo, Soon Yong Sah, Kyoungsoo Lee, Seung Hwan Han, Tae Hoon Ahn, Euk Kyun Shin

Gachon University Gil Medical Center, Incheon, Korea (Republic of)

Background: The aim of the study was to compare the efficacy and safety of second-generation drug-eluting stent (DES) with first-generation DES in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Methods: A total of 1022 patients with STEMI undergoing primary PCI were enrolled from the Korean Multicenter Endeavor (KOMET) trial (Cypher, n=201; Taxus, n=204; Endeavor-Sprint, n=204), the Gil PCI registry (XienceV, n=85; Endeavor-Resolute, n=76), and the Korean Nobori registry (Nobori, n=252). We excluded the patients who had been cardiogenic shock at admission, received thrombolytic therapy or had no follow-up data at 1 year. Major adverse cardiac event (MACE), defined as the composite of cardiac death, recurrent myocardial infarction (MI), or target lesion revascularization at 1 year, were compared in patients treated with the first-generation DES (Cypher, Taxus and Endeavor-Sprint; n=609) versus second-generation DES (Xience V, Endeavor-Resolute and Nobori; n=413).

Results: Baseline characteristics were similar between patients treated with the first- and the second-generation DES except history of MI which was more prevalent in the second-generation DES group than in the first-generation DES group (6.1% vs. 2.0%, p=0.01). The cumulative incidence of MACE rate was 6.4% for the first-generation DES group and 1.2% for the second-generation DES group at 1-year follow-up (p<0.001, Figure). One-year recurrent MI and TLR rate were significantly lower in the second-generation DES group than those in the first-generation DES (0.2% vs. 2.0%, p=0.016; 0.2% vs. 2.8%, p=0.002, respectively). However, cardiac death rate was not significantly different in the both group (0.7% vs. 1.6%, p=0.261). There was a trend towards a lower rate of stent thrombosis (definite or probable) in patients treated with the second-generation DES compared to the first-generation DES (1.6% vs. 0.2%, p=0.058).

Conclusion: As compared with the first-generation DES, the use of the second-generation DES in patients with STEMI undergoing PCI showed lower rates of MACE, recurrent MI and TLR at 1 year. There was a trend towards a lower rate of stent thrombosis with the second-generation DES compared to the first-generation DES.